| Objective:Tiaogan capsule combination of lamivudine in chronic hepatitis B patients with liver and gallbladder damp heat of the clinical symptoms, liver function, virological response and resistance to interference.Methods:Select January 2008-April 2010 the second Chinese Medicine Hospital of Guangdong Province of chronic hepatitis B liver and gallbladder damp heat of 60 patients were randomly divided into treatment and control groups, prospective controlled study, treatment group Tiaogan capsule combined use of lamivudine, lamivudine alone control group, capsule, after 2 years of therapy in patients with clinical symptoms were observed and compared the patients with liver function, serum hepatitis B two pairs of semi-, HBV-DNA, YMDD mutation and other indicators change. Tiaogan capsule of Chinese medicine combined with lamivudine is to improve clinical efficacy, enhanced antiviral activity and reduce the impact of lamivudine resistance and make an objective evaluation.Results:1,Treatment group after 2 years treatment of anorexia from 70% to 6.67%, X2 value of 25.45, compared with the group before treatment was significantly (P<0.05); control group after 2 years treatment of anorexia incidence from 70% to 16.67%, X2 value of 17.37, compared with the group before treatment was significantly (P<0.05);2,Treatment group after treatment for 2 years the incidence of fatigue from 86.67% to 10.00%, X2 value of 35.30, compared with the group before treatment was significantly (P<0.05), compared with the control value of 4.65 X2 statistically significant (P<0.05); control group after treatment for 2 years the incidence of fatigue from 90% to 33.33%, X2 value of 20.37, compared with the group before treatment was significantly (P<0.05); 3,Treatment group, abdominal distention after 2 years The incidence rate increased from the original 40.00% down to 6.67%, X2 value of 9.31, compared with the group before treatment was significantly (P<0.05); control group, abdominal distention after 2 years The incidence rate increased from 33.33% to 10.00%, X2 value of 4.81, compared with the group before treatment was significantly (P<0.05);4,Treatment group 2 years after treatment the incidence of liver pain from 36.67% to 6.67%, X2 value of 7.95, compared with the group before treatment was significantly (P<0.05); control group 2 years after treatment The incidence of pain in the area from 36.67% to 13.33%, X2 value of 4.35, compared with the group before treatment was significantly (P<0.05);5,Treatment group after 1 years of therapy ALT value of liver function before treatment, compared with the t value of 15.41 was significant (P<0.05), compared with the control group, t=3.54, statistically significant (P <0.05),2 years after treatment than before treatment with the group t value of 19.93 was significant (P<0.05); the control group after 2 years of therapy ALT value of liver function after 1 year of treatment compared with the group treated with t=14.85 statistically significant (P<0.05), treatment 2 years after the treatment group compared with the group t=19.62 was significant (P<0.05);6,AST values of liver function in treatment group 1 year after treatment the treatment group compared with the group t=16.73 significant (P<0.05), compared with the control group, t=2.76, statistically significant (P <0.05), treatment 2 years after the treatment group compared with the group t value of 18.91 was significant (P<0.05); control group, AST values of liver function after 1 year of treatment the treatment group compared with the group t value of 16.02 was significant (P<0.05), treatment 2 years after the treatment group compared with the group t value of 19.48 was significant (P<0.05);7,Treatment group 2 years after treatment,the HBeAg seroconversion rate was 56.67%, X2 value of 4.34, compared with the control group was statistically significant (P<0.05);8,Treatment group 2 years after treatment, the HBeAg/anti-HBe seroconversion rate was 53.67%, X2 value of 4.34, compared with the control group was statistically significant (P<0.05); 9,Treatment group 2 years after treatment, the HBV-DNA negative conversion rate was 86.7%, X2 value of 5.2, compared with the control group was statistically significant (P<0.05);10,Treatment group 2 years after treatment, the serum variation was 6.7%, X2 value of 4.32, compared with the control group was statistically significant (P<0.05);Conclusion:The results show that the Tiaogan capsule combined with lamivudine in patients with clinical symptoms and signs to improve liver function and also better than lamivudine efficacy in inhibiting hepatitis B virus replication context, HBV-DNA negative, HBeAg negative and serum conversion higher than lamivudine, combination therapy can also reduce resistance to lamivudine alone, and patients with good compliance and no adverse reactions. Suggesting that the two drugs is safe, can better play a long course of the clinical role of inhibition of hepatitis B virus, and can reduce the rate of lamivudine resistance, and thus worthy of clinical application...
|
PDF Full Text Request